Articles by Daniel Marsh
Meta Shares Rebound Amid Geopolitical Tensions, Traders Eye Key Events
Meta Platforms stock bounced back from early losses, trading near $648 after geopolitical concerns sparked a market sell-off. Key events this week include a Morgan Stanley conference appearance and the February jobs report.
Netflix Shares Dip Despite JPMorgan's Bullish Call After $2.8B Deal Termination
Netflix shares declined slightly despite JPMorgan initiating coverage with an optimistic outlook, as investors assess the company's path forward after walking away from a major acquisition and receiving a substantial termination payment.
Netflix Shares Dip Despite JPMorgan's Bullish Call After $2.8B Deal Termination
Netflix shares edged lower despite JPMorgan initiating coverage with an Overweight rating and $120 price target. The streaming company recently received a $2.8 billion termination fee after walking away from the Warner Bros. acquisition.
Tesla Shares Dip Amid Oil Surge, Mixed European Data
Tesla shares declined in early trading as geopolitical tensions lifted oil prices and investors assessed conflicting European sales figures. The company also increased the price of its dual-motor Cybertruck.
Tesla Shares Drop Amid Oil Spike, Mixed European Data
Tesla shares declined 2.6% to $391.92 Monday, pressured by rising oil prices and uneven European demand signals. The automaker raised the dual-motor Cybertruck price to $69,990.
Tesla Stock Dips Amid Oil Surge, Mixed European Data; Cybertruck Price Hike
Tesla shares declined in Monday trading as geopolitical tensions lifted oil prices and European demand signals were uneven. The automaker also raised the price of its dual-motor Cybertruck.
BioCryst Shares Slip on New HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO and targets a late-2027 regulatory submission.
BioCryst Shares Slip on New Hereditary Angioedema Drug Data
BioCryst Pharmaceuticals shares fell premarket following new clinical data for its hereditary angioedema candidate navenibart. The company reaffirmed its 2026 revenue outlook and plans a Phase 3 filing by late 2027.
BioCryst Shares Slide on HAE Drug Data, Focus Shifts to Cowen Conference
BioCryst Pharmaceuticals shares fell nearly 3% in premarket trading following new clinical data for its hereditary angioedema candidate navenibart. The company maintained its 2026 revenue outlook for ORLADEYO.
Vanguard S&P 500 ETF Slides on Iran Strike Fears, Oil Surge
Vanguard's S&P 500 ETF declined approximately 1% in Monday's premarket trading following military action against Iran, with oil prices jumping 8% and gold futures rising 3.4% as investors sought safety.
